Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T, Grincuka E, Masuda N, McNally V, Ross G, Brewster M, Marier JF, Trinh MM, Garg A, Nijem I, Visich J, Lum BL, Baselga J. Cortés J, et al. Among authors: nijem i. Anticancer Drugs. 2013 Nov;24(10):1084-92. doi: 10.1097/CAD.0000000000000016. Anticancer Drugs. 2013. PMID: 23969513 Clinical Trial.
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S. Xin Y, et al. Among authors: nijem i. J Clin Pharmacol. 2013 Nov;53(11):1103-11. doi: 10.1002/jcph.148. Epub 2013 Aug 7. J Clin Pharmacol. 2013. PMID: 23922054 Clinical Trial.
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Quartino AL, Li H, Jin JY, Wada DR, Benyunes MC, McNally V, Viganò L, Nijem I, Lum BL, Garg A. Quartino AL, et al. Among authors: nijem i. Cancer Chemother Pharmacol. 2017 Feb;79(2):353-361. doi: 10.1007/s00280-016-3218-0. Epub 2017 Jan 10. Cancer Chemother Pharmacol. 2017. PMID: 28074265 Free PMC article.
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP, Wynne C, Kågedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg A. Kirschbrown WP, et al. Among authors: nijem i. J Clin Pharmacol. 2019 May;59(5):702-716. doi: 10.1002/jcph.1362. Epub 2018 Dec 19. J Clin Pharmacol. 2019. PMID: 30570763 Free PMC article. Clinical Trial.
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
Kirschbrown WP, Kågedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, von Minckwitz G, Bines J, Garg A. Kirschbrown WP, et al. Among authors: nijem i. Cancer Chemother Pharmacol. 2019 Jun;83(6):1147-1158. doi: 10.1007/s00280-019-03826-1. Epub 2019 Apr 11. Cancer Chemother Pharmacol. 2019. PMID: 30976844 Free PMC article. Clinical Trial.
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.
Kirschbrown WP, Wang B, Nijem I, Ohtsu A, Hoff PM, Shah MA, Shen L, Kang YK, Alsina M, Girish S, Garg A. Kirschbrown WP, et al. Among authors: nijem i. Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10. Cancer Chemother Pharmacol. 2019. PMID: 31183514 Free PMC article. Clinical Trial.
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Salgia R, et al. Among authors: nijem i. Clin Cancer Res. 2014 Mar 15;20(6):1666-75. doi: 10.1158/1078-0432.CCR-13-2070. Epub 2014 Feb 3. Clin Cancer Res. 2014. PMID: 24493831 Clinical Trial.
Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
Li C, Wang B, Lu D, Jin JY, Gao Y, Matsunaga K, Igawa Y, Nijem I, Lu M, Strasak A, Chernyukhin N, Girish S. Li C, et al. Among authors: nijem i. Cancer Chemother Pharmacol. 2016 Sep;78(3):547-58. doi: 10.1007/s00280-016-3099-2. Epub 2016 Jul 16. Cancer Chemother Pharmacol. 2016. PMID: 27423671
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
Li C, Agarwal P, Gibiansky E, Jin JY, Dent S, Gonçalves A, Nijem I, Strasak A, Harle-Yge ML, Chernyukhin N, LoRusso P, Girish S. Li C, et al. Among authors: nijem i. Clin Pharmacokinet. 2017 Sep;56(9):1069-1080. doi: 10.1007/s40262-016-0496-y. Clin Pharmacokinet. 2017. PMID: 27995530 Clinical Trial.
18 results